Antagonist Protocol in IVF
Can Antagonist Protocol be the Protocol of Choice in in Vitro Fertilization Patients?
1 other identifier
interventional
200
1 country
1
Brief Summary
The antagonist protocol in a novel method of stimulation in the in vitro fertilization (IVF) patients. It has been tried in poor responders, polycystic ovary (PCO) patients and normal females undergoing IVF. Can it be used with the same efficacy in all patients?
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_2
Started Jan 2015
Shorter than P25 for phase_2
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2015
CompletedFirst Submitted
Initial submission to the registry
January 7, 2015
CompletedFirst Posted
Study publicly available on registry
January 12, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
April 1, 2016
CompletedFebruary 15, 2016
February 1, 2016
7 months
January 7, 2015
February 12, 2016
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
number of oocytes collected and fertilized
6 months
Study Arms (3)
Normal
ACTIVE COMPARATORHuman menopausal gonadotrophin IM daily was administrated from day 2 of the cycle. The Gonadotropins releasing hormone antagonist GnRH ant (Cetrotide, Serono, Geneva, Switzerland) was given when the leading follicle was from 12 to 14 mm, at a daily dose of 0.25 mg SC.
Poor responders
ACTIVE COMPARATORHuman menopausal gonadotrophin IM daily was administrated from day 2 of the cycle. The Gonadotropins releasing hormone antagonist GnRH ant (Cetrotide, Serono, Geneva, Switzerland) was given when the leading follicle was from 12 to 14 mm, at a daily dose of 0.25 mg SC
Polycystic ovarian disease
ACTIVE COMPARATORHuman menopausal gonadotrophin IM daily was administrated from day 2 of the cycle. The Gonadotropins releasing hormone antagonist GnRH ant(Cetrotide, Serono, Geneva, Switzerland) was given when the leading follicle was from 12 to 14 mm, at a daily dose of 0.25 mg SC
Interventions
Eligibility Criteria
You may qualify if:
- age: 20- 44 years
- Poor responder females according to Bologna criteria
- Polycystic ovarian disease females according to Rotterdam criteria
- Females with infertility causes other than poor responders, or PCO; male factor or tubal block
You may not qualify if:
- refusal to get enrolled in the study
- cases of infertility due to severe male factor
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Woman's Health University Hospital, Egyptlead
- Cairo Universitycollaborator
Study Sites (1)
Kasr el aini hospital
Cairo, Cairo Governorate, Egypt
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Dina M Dakhly, MD
Cairo University
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- lecturer of obstetrics and gynecology
Study Record Dates
First Submitted
January 7, 2015
First Posted
January 12, 2015
Study Start
January 1, 2015
Primary Completion
August 1, 2015
Study Completion
April 1, 2016
Last Updated
February 15, 2016
Record last verified: 2016-02